FDA approves SunPharma’s Lexervi for treatment of adults with severe alopecia areata

Leqselvi is classified as a novel oral Janus kinase inhibitor that targets the JAK1 and JAK2 pathways, which are thought to be involved in the autoimmune response that causes alopecia areata.